Conclusion
congenital anomalies, anemia
ADVERSE EVENTS, ANEMIA DURING PREGNANCY, ANEMIA
In conclusion, based on the findings of our study, Mojeaga should be considered a new adjuvants to standard-of-care option for pregnant and puerperal women with anemia. Mojeaga remedy is safe for treating anemia during pregnancy and puerperium without increasing the incidence of congenital anomalies, low birthweight, preterm labor/rupture of membranes or other adverse events. These findings, therefore, suggest the potential benefit of Mojeaga for treating patients with anemia and support for further adequately powered confirmatory trials investigating the efficacy and safety of Mojeaga remedy.